Ann: Successful Landmark Study in Paediatric ASD, page-9

Added to position this morning at 6.2c. The only thing I can think that is holding this back today is the risk of a cap raise. But any cap raise will be hotly contested and if they have any third party deals that are well progressed, these will be announced before a cap raise (i.e higher SP). So no rush to raise money this month.

Other thought is that the announcement is lacking detail on efficacy as the outcomes are very subjective (i.e. carer observations) but that is the nature of ASD.

To think that this was +8c pre trial results, pre clinical studies on MS, Prednisone etc, this is still a steal IMHO.

What is also encouraging is the short turnaround to phase 3... Expected to commence in Q3 Calendar 2022 (take that with a grain of salt - but they have stated for some time that they have been planning phase 3 while this study is running)....

Just need the market to take a look outside of battery minerals for 5 minutes...